Astrazeneca Earnings Preview: Can This Streak Continue?

Astrazeneca (NYSE:AZN) will report earnings before markets open on Thursday, April 25th. AstraZeneca PLC is a holding company. Through its subsidiaries, the Group researches, manufactures and sells pharmaceutical and medical products. The Group focuses its operations on seven therapeutic areas: Gastrointestinal, Oncology, Cardiovascular, Respiratory, Central Nervous System, Pain Control, Anaesthesia and Infection.

Here is your Cheat Sheet to Astrazeneca Earnings:

Earnings Expectations: Analysts expect earnings of $1.33 per share on revenues of $6.53 billion. Currently, the company’s P/E ratio stands at 10.25.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $1.39 to a profit $1.21. For the current year, the average estimate is a profit of $5.38, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Astrazeneca has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 31,600 32,800 33,270 33,590 27,970
Diluted EPS ($) 4.20 5.19 5.57 7.30 4.98

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 8,656 7,349 6,660 6,682 7,282
Diluted EPS ($) 1.16 1.28 1.27 1.21 1.22

Past Performance:
Astrazeneca has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]